Conclusions
While initially MR expression was thought to be restricted to kidney epithelial cells, numerous translational studies have shed light on the complex (patho-)physiological importance of MR expression in many CV cells such as cardiomyocytes, endothelial cells and VSMCs. MRA are an essential part of medical therapy for HF and resistant hypertension for many years. Currently the novel non-steroidal MRA finerenone is introduced into clinical practice for patients with diabetic kidney disease to reduce both progression of renal disease and CV events.